
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)13248-3
10.1016/j.heliyon.2024.e37217
e37217
Review Article
Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics
Muteeb Ghazala a
Khafaga Doaa S.R. b
El-Morsy Manar T. c
Farhan Mohd de
Aatif Mohammad maahmad@kfu.edu.sa
f⁎
Hosney Mohamed mhosney@cu.edu.eg
mhosney@sci.cu.edu.eg
g⁎⁎
a Department of Nursing, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia
b Health Sector, Faculty of Science, Galala University, New Galala City, 43511, Suez, Egypt
c Biotechnology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt
d Department of Chemistry, College of Science, King Faisal University, Al Ahsa, 31982, Saudi Arabia
e Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al Ahsa, 31982, Saudi Arabia
f Department of Public Health, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia
g Zoology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt
⁎ Corresponding author. maahmad@kfu.edu.sa
⁎⁎ Corresponding author. mhosney@cu.edu.egmhosney@sci.cu.edu.eg
30 8 2024
30 9 2024
30 8 2024
10 18 e3721718 1 2024
6 8 2024
29 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Tumor-associated macrophages (TAMs) promote tumor advancement in many ways, such as inducing angiogenesis and the formation of new blood vessels that provide tumors with nourishment and oxygen. TAMs also facilitate tumor invasion and metastasis by secreting enzymes that degrade the extracellular matrix and generating pro-inflammatory cytokines that enhance the migration of tumor cells. TAMs also have a role in inhibiting the immune response against malignancies. To accomplish this, they release immunosuppressive cytokines such as IL-10, and TAMs can hinder the function of T cells and natural killer cells, which play crucial roles in the immune system's ability to combat cancer. The role of TAMs in breast cancer advancement is a complex and dynamic field of research. Therefore, TAMs are a highly favorable focus for innovative breast cancer treatments. This review presents an extensive overview of the correlation between TAMs and breast cancer development as well as its role in the tumor microenvironment (TME) shedding light on their impact on tumor advancement and immune evasion mechanisms. Notably, our study provides an innovative approach to employing nanomedicine approaches for targeted TAM therapy in breast cancer, providing an in-depth overview of recent advances in this emerging field.

Keywords

Tumor associated macrophages
Breast cancer progression
M1
M2
Angiogenesis
Metastasis
Immunosuppression
==== Body
pmc1 Introduction

Tumor-associated macrophages are the most prominent immune cells found in malignancies [1]. TAMs constitute almost 50 % of the overall immune cells that infiltrate the tumor [1]. TAMs are commonly categorized into two distinct subgroups, known as M1 and M2 [2,3]. TAMs carry out a diverse array of roles through various phenotypes that are influenced by dynamic interactions, ultimately enhancing tumor growth [1,4]. The TAM1 phenotype is regarded as proinflammatory due to its ability to engage in phagocytosis and recognize cancer cells [5]. TAM1 induces tumor cell death while also promoting the production of proinflammatory cytokines, such as IL-12 and IFN-γ. TAM1 also expresses major histocompatibility complex (MHC) class II, which enhances their ability to display antigens on their surface [1,4]. On the other hand, the TAM2 phenotype has a function in reducing inflammation and is triggered by IL-13 or IL-4, leading to the generation of molecules that promote fibrosis. The prevalence of TAM2 increases, leading it to become the predominant subtype of TAMs in the tumor microenvironment [1]. TAM2 is recognized as a prominent “tumor promotor” that stimulates the development, invasion, and spread of tumor cells in breast cancer [4,6]. The inhibition of tumor growth was achieved by repolarizing TAMs into the TAM1 phenotype, taking advantage of the flexibility of TAMs [7]. An imbalance in the populations of M1 and M2 cells might lead to pathogenic occurrences [8,9]. An overabundance of M1 activation has been linked to the onset of chronic inflammatory disorders, whereas unregulated proliferation of M2 macrophages might result in significant immunological suppression [9,10].

Breast Cancer (BC) is highly frequent among women. Although surgical techniques and chemotherapy offer promise for recovery, the prognosis of BC deteriorates as the disease advances [11]. Different factors, including tumor grade, size, and nodal involvement, affect the prognosis of BC [11]. It has been confirmed that many molecular subtypes have unique characteristics and responses to treatment [12]. Additionally, a substantial association exists between an elevated level of TAM and various other factors, such as larger tumor size, basal phenotype, histologic grade, and blood vascular invasion [1,13]. Tumors can attract stromal cells such as, fibroblasts, immunological cells, and vascular cells by producing growth factors, cytokines, and chemokines. The recruiting process, in addition to the release of growth-promoting signals and tissue remodeling, plays a significant role in the development of TME, which has a substantial impact on tumor initiation, progression, metastasis, vascularization, and treatment responses [12].

Nanotechnology is essential for particularly targeting TAMs in the treatment of breast cancer [14]. Liposomes, polymeric nanoparticles, and micelles are types of nanocarriers that have been employed to transport chemotherapeutic agents and gene therapies to breast tumor cells [14,15]. This approach improves the effectiveness of treatment by increasing cytotoxicity and reducing the development of drug resistance [14,16]. In addition, researchers have created nanocarriers that respond to stimuli and can effectively target breast tumors. These nanocarriers are also capable of remodeling the tumor microenvironment and repolarizing macrophages to enhance antitumor immunity [15]. In addition, a versatile nanoplatform has been created to enhance the infiltration of T lymphocytes, eliminate tumor cells, and regulate immune responses by targeting PD-L1 and CD47 signals in breast cancer. This results in a more potent anti-tumor immune response and a shift of TAMs from protumor M2 like to antitumor M1 like phenotypes [17]. In summary, nanotechnology provides an opportunity to improve the effectiveness of breast cancer therapy by specifically targeting TAMs and regulating the immune response. Several treatment strategies primarily concentrate on specifically targeting cancer cells while disregarding the significant contribution of the TME in the formation and advancement of cancer [18]. In view of the evolving landscape of breast cancer research, our study stands out by focusing on targeted therapy for TAMs in the context of nanotechnology. We hope to transform breast cancer treatment by harnessing the unique features of nano carriers, providing a new perspective on TAM-targeted therapies. This review article not only bridges the gap between TAM biology and therapeutic innovation, but also develops the way for novel breast cancer treatment strategies that show significant promise for enhancing antitumor immune response and improving patient outcomes.

2 Methodological approaches

This review was conducted by performing a comprehensive search of the literature to gather information on the role of tumor-associated macrophages in breast cancer and the emerging nanomedicine approaches for targeted TAM therapy. The inclusion criteria for this review encompassed peer-reviewed original research articles, review articles and clinical trials that specifically focus on TAMs in the context of breast cancer, their mechanisms of promoting tumor progression, and therapeutic strategies targeting TAMs using nanotechnology. Studies involving human subjects, as well as in vivo and in vitro models, were included. Articles had to be published in English between 2004 and 2024 to ensure the inclusion of the most recent and relevant research. The exclusion criteria eliminated studies that did not directly address TAMs in breast cancer, non-English publications, duplicate studies, and non-research articles such as editorials and commentaries. Databases searched included PubMed, Web of Science, Scopus, and Google Scholar using keywords such as tumor-associated macrophages, breast cancer, tumor microenvironment, angiogenesis, nanomedicine, and targeted therapy. Data extraction focused on study design, population, key findings related to TAMs and breast cancer, therapeutic strategies, and outcomes. The quality of included studies was assessed using standardized criteria appropriate for the type of research.

3 Breast cancer

Worldwide, breast cancer is the most prevalent form of cancer and is recognized as a major contributor to cancer-related deaths in developing as well as developed countries. Approximately 2.3 million women globally received a breast cancer diagnosis in 2020, resulting in 685,000 fatalities. By the year 2023, the United States is projected to see the diagnosis of breast cancer in about 300,000 women. Approximately 20 % of individuals who are newly diagnosed with breast cancer have a familial history of the disease [19]. The prevalence of breast cancer continues to be a major worldwide health issue, requiring the creation of creative and efficient treatment approaches. Breast cancer is a prevalent malignancy in women and may also affect males, but less often. Recognizing the many subtypes of breast cancer is crucial for adapting therapy strategies for individual patients. This information may be useful in achieving a correct diagnosis, designing treatment strategies, and improving patient prognosis [20]. Multiple studies have demonstrated that various factors, such as age, race, socioeconomic status, genetic factors like BRCA mutations, hormonal factors like age at menarche, parity, age at first full-term pregnancy, breastfeeding, and lifestyle-related factors like diet, physical activity, alcohol use, and tobacco use, are all linked to a higher risk of breast cancer [21].

4 Macrophages in breast cancer

Macrophages, a type of white blood cell responsible for phagocytosis, play a vital role in the human immune system [18,22]. They contribute to both innate and cellular immunity [22]. Originating from monocytes, which differentiate from precursor cells in the bone marrow [7,22]. TAMs possess a variety of types, including conventional types of M1 and M2 cells, as well as TCR+ and CD169+ macrophages [23]. Initially, TAMs were mistakenly classified as M2 cells due to their similar abundance around the tumor, secretion of various cytokines, and promotion of metastasis in breast cancer cells [23,24]. However, unlike M2 cells, TAMs do express INOS and the CD200 receptor [25]. Macrophages can follow two activation pathways upon exiting blood vessels, resulting in the formation of M1 or M2 macrophages [15,26]. These macrophage subtypes exhibit distinct characteristics and immunophenotypes. Notably, the NF-kB signaling pathway participates in the polarization of M1 cells, while M2 cells do not rely on this pathway [27]. M1 macrophages produce pro-inflammatory cytokines, possess strong antigen-presenting abilities, and promote immune responses against bacteria and tumor cells [28]. Conversely, M2 macrophages primarily release immunosuppressive cytokines, have limited antigen-presentation capabilities, and contribute to tissue repair, wound healing, and blood vessel formation [10,28]. Traditionally, macrophages have been recognized as phagocytes and eliminators of tumor cells, aiding in cancer cell clearance [29]. Macrophages are a major component of immune infiltration in breast cancer cells [30]. However, in breast cancer patients, macrophages prefer to accumulate in malignant tissues and their environs. This buildup leads to the release of reduced immune factors, enhanced osteolysis, promotion of lymphatic metastasis, and resistance to radiation and chemotherapy, promoting tumor growth and enabling recurrence, particularly in patients with negative prognoses [31]. Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in women worldwide [32]. Breast cancer cells and their microenvironment have been shown in recent studies to eliminate the production of inflammatory response factors in breast cancer and surrounding tissue [5]. As a result, M2 macrophages aggregate, and M0/M1 macrophages convert into M2 macrophages, culminating in the growth of TAMs [4,33].

5 Macrophage activation and mechanism of action

Through Fcγ receptors on the surface of tumor cells, like CD20 and calreticulin, M1 macrophages may recognize and target tumor cells, which facilitates the phagocytosis of tumor cells by M1 macrophages [16,34,35]. Additionally, M1 macrophages stimulate T cells, improve the expression of CD4 and CD8, induce immune responses against tumor cells, and inhibit tumor formation [34]. These “eat me” signal molecules are specific to cancer cells and are absent in normal cells. They are essential for the balance of “eat me” and “don't eat me” signals when macrophages are phagocytosing breast cancer cells [5]. Macrophages are capable of specifically phagocytosing malignant cells while protecting normal cells by blocking the CD47-SIRP signaling pathway [34,36]. Nevertheless, recent research has shown that enhancing macrophage-mediated anti-tumor activity requires more than just lowering inhibitory signals like CD47 [34]. Two signals are necessary for the effective activation of macrophages. First, there needs to be an activation signal a Toll-like receptor agonist, for example. Secondly, an additional signal, such as a CD47 inhibitor, is needed to reduce the threshold for anti-cancer effects [37]. Expanding on this observation, CPG, a Toll-like receptor agonist, was utilized to promote macrophages, initiating the first signal. TME has been found to foster tumor development, but the presence of M1 cells via the TME mitigates the TME's impact on breast tumors. Conversely, the presence of M2 cells promotes tumor growth. Therefore, reprogramming M2 macrophages into the M1 phenotype is imperative [38]. The utilization of cGAMP-NP has been shown to enhance the expression of MHC and co-stimulatory molecules, elevate CD4+ and CD8+ expression, and result in T cell activation by stimulating IFNγ through STING, as illustrated in Fig. 1.Fig. 1 Activation of tissue macrophage. Microbes cytokine (IFNγ), fibroblast growth factors (FGF), platelet derived growth factor (PDGF)and Interleukin 4 (IL-4).

Fig. 1

Consequently, this results in the eradication of breast cancer tumors and facilitates the conversion of M2 macrophages into the M1 phenotype [39]. Furthermore, the cationic polysaccharide spermine pullulan has exhibited the ability to augment the function of TLR1, TLR2, and TLR3 receptors, promote the ERK pathway, increase CD4 and CD8 levels in tissues, and decrease CD31 expression, thereby promoting the polarization of M0/M2 macrophages toward the anticancer M1 phenotype [40]. Further, it was recently shown that an extract made from the herb combination of Scutellaria barbata and Hedyotis difusa upregulates the expression of miR155 in M2 macrophages while downregulating it in M1 macrophages. Additionally, YDW11 prevents breast cancer cells from migrating by inhibiting macrophage polarization toward the M2 phenotype [40].

6 TAMs as modulators of the breast cancer tumor microenvironment

TAMs have received considerable attention in cancer research, and scientists are currently working on them as a cancer therapeutic target. TAMs gather in large quantities in the vicinity of tumors and have a substantial impact on cancer growth, leading to their being labeled “traitors” [41]. Thus, M2 cells aid in the restructuring of blood vessels and the formation of lymphatic channels, both of which contribute to the progression of cancer [24,37]. Furthermore, tumor cells actively enhance M2 cell synthesis and recruit more M2 cells to the tumor location [24,42]. They also produce additional cytokines that support M0 cell transformation into TAMs and control certain microRNAs, ERK, P53, and other various signaling pathways that promote M1 to M2 cell conversion [43].

7 Role of TAMs in breast cancer development

TAMs encompass a heterogeneous population of cells with diverse functional effects in both steady-state and pathological conditions. The composition and behavior of TAMs are regulated by various mechanisms, including soluble factors derived from tumor cells, alterations in tumor metabolism, interactions with other immune cells, and additional factors [44]. While bone marrow monocytes are the primary source of TAMs in tumors, current evidence indicates that the recruitment of circulating inflammatory monocytes is critical for TAM accumulation, which is controlled by TME factors such as chemokines and cytokines [45]. Monocytes originating from bone marrow form long-lived TAMs within the TME. TAMs can be found in both hypoxic and normoxic regions of the tumor [46]. Importantly, TAMs not only adapt to their TME location but also reciprocally shape the composition of the surrounding TME [47]. The localization and extent of TAM infiltration pose challenges for targeted interventions in breast tumors [47]. TAMs predominantly exhibit an M2 phenotype, often referred to as pro-tumor, as they facilitate cancer cell proliferation, angiogenesis, and metastasis through distinct anti-inflammatory mechanisms [48,49] as illustrated in Fig. 2.Fig. 2 The role of tumor-associated macrophages (TAM) in cancer cell progression.

Fig. 2

It is worth noting that not all inflammation is beneficial during homeostasis, as prolonged inflammation can promote malignant cell transformation and tumor growth [24,36]. TAMs enhance tumor progression by releasing growth factors, such as epidermal growth factor receptor (EGFR), which result in breast cancer proliferation [39]. Human breast cancer cell lines and animal models illustrate that breast tumor cells can produce colony-stimulating factor (CSF)-1 (macrophage [M]-CSF) and CCL2, which are considered the most significant attractants and growth factors for TAMs. CSF-1 and its receptor (CSF-1R) assist in the regulation of macrophages; CSF-1R and/or CSF-1 expressions are potentially associated with a poor breast cancer prognosis [50]. The invasive capacity is increased by the production of CSF-1 from cancer cells [51]. CSF-1 stimulation not only increases TAM recruitment but also results in the development of a large density of vascular networks that promote tumor growth [51].

7.1 TAMs promote tumor invasion and metastasis

Cells with pleiotropic functions release exosomes, which are small lipid bilayer particles that are typically differentiated based on size and markers [52]. Previous studies reported that pleiotropic cells regulate the intracellular pathway involved in all stages of breast tumor development until metastasis dissemination [52]. Both TAMs and tumor cells undergo alterations in cellular metabolism, which shape their functional phenotype in a mutually influencing way [53,54]. TAMs can regulate multiple mechanisms associated with the dissemination of carcinoma cells. For instance, TAMs secrete proteolytic enzymes such as matrix metalloproteinases-2 and 9 (MMP-2 and MMP-9) that can degrade components of the basement membrane, thereby facilitating tumor cell intravasation and spreading in blood and lymphatic vessels [55]. Many studies have demonstrated that tumor-derived exosomes have a significant function in transforming monocyte-derived macrophages into regulatory macrophages [4]. Necrosis is another feature of tumors that is related to both the poorprognosis and the presence of TAMs [56]. Tumors with necrosis-state have a hypoxia area that attracts TAMs, in addition to the polarization of TAMs towards the M2 phenotype by CSF-1 expression and the production of factors that assist in the promotion of tumors and metastasis [56].

7.2 TAMs promote angiogenesis

TAMs enhance angiogenesis in breast cancer cells. TAMs are a rich supply of pro-angiogenic factors, such as SPARC, VEGF, chitinase like proteins, the SEMA and S100A families, and osteopontin [57]. M2 subtypes that are recruited and accumulated within TME play a significant role in angiogenesis by producing proangiogenic factors like vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) [43,57]. These factors enhance blood vessel formation in tumors, which is crucial for facilitating tumor development and metastasis [26]. Small protein molecules can regulate leucocyte transportation, called chemokines, in response to homeostasis or inflammation [58,59]. TAMs and their pro-angiogenic activities may be targeted as a potential treatment approach for breast cancer to reduce tumor angiogenesis and inhibit tumor growth [[60], [61]]. CXCL18 is one of the major chemokines that accumulate in TAMs in breast cancer [62]. CXCL18 promotes tumor growth and invasion in breast cancer by inducing IL-4, IL-13, and IL-10 in TAMs [62]. The direct binding between chemokines and chemokines receptors changes the expression of secondary messengers to promote angiogenesis and inhibit the infiltration of the antitumor cells [63]. Nanocarriers are essential in reducing the development of breast cancer by specifically inhibiting angiogenesis and TAMs [64,65]. Research has demonstrated that nanoplatforms such as Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobodies can impede the movement, infiltration, and growth of cells, thereby effectively restraining the development of blood vessels near cancerous cells and impeding the advancement of tumors [65,66]. In addition, lipopolymeric hybrid nanostructures with spermine tethers have demonstrated targeted uptake by breast cancer cells. This uptake triggers apoptosis and exerts a potent antiangiogenic effect by influencing the VEGF pathway, cell proliferation, invasion, and migration. These findings demonstrate the potential of nanocarriers in combination chemotherapy for effectively inhibiting the progression of breast cancer [67]. Nanotechnology in drug delivery systems shows potential for improving the antiangiogenic effects of breast cancer treatment through precise targeting of tumor cells and their microenvironment.

7.3 TAMs suppress the immune system

TAMs play a role in modulating the effectiveness of T cells and natural killer (NK) cells in eliminating tumor cells. In cases of liver fibrosis, M1 macrophages enhance the population of activated NK cells, release TNF related apoptosis inducing ligand (TRAIL), and induce apoptosis in cancer cells [15]. In mesothelioma, M2 macrophages in pleural effusion show an inverse correlation with T cells in vivo, indicating the potential for targeting macrophages in mesothelioma treatment [68]. Furthermore, TAMs can directly hinder the proliferation of CD8+ T cells through various mechanisms, including arginase- 1 metabolism of L-arginine, iNOS, oxygen radicals, or nitrogen species [59]. TAMs also recruit regulatory T cells (Tregs) through CCL22 [69]. Further suppressing the immune response of T cells against tumors. Experimental removal of TAMs impedes Treg cell recruitment, restrains tumor growth, and reduces the level of CCL20 in mice with xenograft tumors [70,71]. Extensive evidence suggests that inflammation at the tumor site can promote tumor progression. Inflammation and immune evasion are recognized as critical features of cancer. TAMs contribute to cancer related inflammation by promoting the generation of inflammatory T-helper subsets, such as TFH. Toll-like receptor 4 (TLR4) induced inflammation in monocytes plays a crucial role in inducing IL-21+ TFH like cells [2,62]. Through IL-21-IFNγ-dependent pathways, they facilitate plasma cell differentiation and create a favorable environment for M2b macrophages and cancer progression [71,72]. Furthermore, TME can undergo metabolic changes that can also contribute to the immunosuppressive nature of TAMs. Alterations in food availability and metabolic pathways can shift macrophage polarization towards a protumor phenotype, decreasing their capacity to generate an active anticancer immune response [71]. These findings suggest that strategies aimed at influencing the functional activities of inflammatory cells may hold therapeutic benefits in cancer treatment.

8 Targeting pathways for breast cancer suppression

Multiple previous studies have provided evidence of frequent mutations in the Ras gene in human cancer. In breast cancer, elevated expression and activation of Ras have been associated with increased aggressiveness of tumors, suggesting its potential as a prognostic indicator for breast cancer progression [73]. The RAS/RAF/MAPK signaling pathway plays a critical role in regulating cellular processes such as proliferation, survival, and apoptosis [74]. Activation of this pathway can result in the downregulation of PAR4, a tumor suppressor protein that specifically promotes apoptosis in cancer cells [75]. Downregulation of PAR4 has been observed in various cancer types, including breast cancer [74,76]. Silencing PAR4 using RNA interference (RNAi) has been demonstrated to enhance the proliferation of MCF-7 cells. Conversely, increased expression of PAR4 has been shown to reduce the proliferation rate of MCF-7 cells and enhance their sensitivity to docetaxel, a chemotherapy drug [77]. One of the attractive targets for breast cancer treatment is macrophages, which are considered independent cofactors in breast cancer [58]. There are various strategies based on enhancing tumor therapy via TAMs.

8.1 TAMs depletion

One appealing treatment strategy for reducing tumor development and drug resistance is progenitor depletion, also known as TAMs [37,[78], [79], [80]]. Chemotherapeutic drugs, such as doxorubicin and docetaxel, can also stop the growth of tumors in breast cancer by eliminating TAMs [58,64]. Administering monoclonal antibodies coupled with immunotoxins that target antigens expressed by TAMs is an additional approach [78,81]. Bisphosphonate compounds are taken up by macrophages to inhibit their proliferation and induce apoptosis in cancer cells [82,83]. Studies have demonstrated that RNA aptamers and trabectedin can specifically eliminate tumor-associated macrophages and trigger caspase-8-mediated apoptosis through TRAIL receptors, respectively [84]. However, M2pep, which includes a proapoptotic peptide, has been discovered to target and eliminate TAMs, leading to improved survival rates in mice with tumors [85]. Providing the proapoptotic peptide to TAMs alone delayed death and selectively decreased the M2 like TAM population [44].

8.2 Macrophage disruption

Chemokines and CSF1 have important functions in attracting and regulating monocytes within tumors. They play a crucial role in decreasing the release of monocytes from the bone marrow by targeting the CSF1-CSF1R and CCL2-CCR2 signals [15]. Consequently, the infiltration of precursor cells and the differentiation of macrophages are diminished in mammary tumors and areas where metastasis may occur [7,86]. In experimental models of breast cancer, inhibitors of CSF1R signaling have been shown to enhance the effectiveness of chemotherapy or radiotherapy by suppressing tumor growth and the spread of cancer to other parts of the body [15,87].

8.3 TAM reprogramming

M1 and M2 macrophage polarization involve many signaling pathways [27,48]. TAMs are repolarized towards TAM2, which is a tumor inhibitor and proinflammatory [88]. The antiinflammatory cytokine IL-10 can be mediated by STAT3, which has the potential to be employed in the process of reprogramming macrophages from the M1 to M2 phenotype [89]. In cancer, miRNAs have a crucial role in regulating TAM phenotypes by inducing M2 like polarization and preventing CD8+ cytotoxic T lymphocytes from infiltrating tumors [89]. Zoledronic acid (ZA) can also decrease the frequency of tumor-associated macrophages and reverse their polarization from M2 to M1, hence reducing spontaneous mammary carcinogenesis [82,90].

9 Therapeutic agents targeting TAMs

9.1 Small molecule inhibitors and immunomodulators for TAM modulation

Recent studies focused on investigating small molecule inhibitors and immunomodulators to regulate TAMs in the TME [91,92]. TAMs play a significant role in enhancing cancer growth and immune suppression, thereby leading to immune checkpoint inhibitor (ICI) resistance [59]. In preclinical mouse models, inhibition of TAM signaling pathways via a small molecule inhibitor has demonstrated its effectiveness [93]. Among the most promising types of small molecule inhibitors for TAM modulation are colony stimulating factor-1 receptor (CSF-1R) inhibitors and focal adhesion kinase (FAK) inhibitors [91]. By reprogramming the TME and TAMs, CSF-1R inhibitors enhance the eradication of breast cancer by T-cell-mediated mechanisms [92,94]. Furthermore, FAK inhibitors alter TME to enhance an antitumor immune response and reduce the invasion of immunosuppressive cells, such as TAMs [3]. The combination of small-molecule inhibitors with ICI presents an opportunity to enhance the efficacy of immunotherapy by specifically targeting TAMs.

9.2 MicroRNA-based therapeutics for TAM targeting

MicroRNA-based therapies for breast cancer have shown promising results, especially when paired with immune checkpoint inhibitors (ICIs) [36]. Furthermore, miRNAs actively contribute to the advancement of breast cancer by affecting stem cell production, initiation, invasion, metastasis, and angiogenesis [95]. Researchers have studied various delivery technologies, such as nanoparticles, liposomes, and viral vectors, to efficiently target breast cancer cells for miRNA delivery [96]. Developing techniques that target dysregulated miRNAs in TAMs could aid in the remodeling of TME [96,97]. Several miRNAs have been discovered that target macrophage genes as well as influence TAM polarization [97]. MiR-155, for example, is a microRNA that has been found to target TAMs in breast cancer. It can block TAM- M2 -like polarization and stimulate an anticancer immune response [98]. A different approach to microRNA that can be targeted in TAMs in TNBC is miR-146a. It inhibits TAM protumor activities while enhancing the antitumor immune response [98]. Targeting TAMs using microRNAs can potentially improve the efficacy of breast cancer treatment by modulating the tumor microenvironment and enhancing the antitumor immune response. Further research and development of these therapies may lead to improved treatment outcomes for breast cancer patients.

9.3 Antibody-based therapies for TAM depletion or reprogramming

In recent years, antibody-based therapies have demonstrated clinical efficacy and safety as a treatment for breast cancer [13]. Monoclonal antibodies (mAbs) have recently been approved as cancer therapies, with remarkable effectiveness [13,95]. Antibody-based treatments targeting TAM depletion or reprogramming in breast cancer have shown progress in recent years [99,100]. TAM depletion has been found to generate a favorable environment for delivering antiprogrammed cell death protein 1 (PD-1) antibodies, hence improving immunotherapeutic efficacy [94]. On the other hand, some targeted therapeutic techniques, such as the use of toxin-conjugated monoclonal antibodies, entail the depletion of M2 [7,71]. Therefore, antibody-based therapeutics can target and treat breast cancer via TAM depletion or reprogramming, hence providing novel tools for therapy.

10 TAMs and drug resistance

In breast cancer treatment, the most difficult challenge is drug resistance [101]. According to recent studies, TAMs are associated with drug resistance [102]. TAMs are a crucial component of TME, and their impact on breast cancer chemotherapeutic resistance cannot be neglected [101]. TME consists of numerous cell types, extracellular matrix, and soluble substances. It has a significant impact on treatment efficacy, which is referred to as environmental mediated drug resistance (EM-DR) [103]. TAMs are one of TIME, which are critical for drug resistance via metabolic reprogramming to induce tumor angiogenesis [101]. As well as the secretion of inflammatory cytokines and chemokines such as TNF-α, IL-6, IL-10, and CCL18 [101]. Secretion of IL-10, which is responsible for the regulation of BCL-2 and STAT3 expressions, induces the activation of the IL-10-STAT3-BCL2 pathway in breast cancer, which enhances drug resistance [71]. TAMs cause immune therapy resistance by suppressing the functions of T-cells [101]. Doxorubicin (DOX) is a chemotherapeutic drug that is frequently used to treat breast cancer [101]. TAMs can increase the level of FABP5 and PPAR in malignant breast cells, activating the CaMKII signaling pathway and leading to DOX resistance [5,104]. TAMs can cause a buildup of ATP binding cassette (ABC) transporters, which are proteins that eliminate DOX from breast cancer cells, resulting in DOX resistance [81]. Furthermore, combining TAM-targeted medicines with conventional chemotherapeutics can help improve the prognosis [105]. Overall, TAMs could affect the response of drugs to various types of cancer, and targeting these types of cells could be a powerful approach to reduce drug resistance and increase therapy effectiveness.

11 Nanoimmunotherapies approaches of TAM

Nanotechnology is an interdisciplinary scientific field that encompasses various types of nanoparticles and novel nanodevices used in diverse areas of research [106,107]. Its application in tumor diagnosis aims to detect malignancies at an early stage, reducing the number of patients with advanced cancer [108,109]. Nanotechnology research and technology present advancements in various fields such as materials and manufacturing, nanoelectronics, healthcare and medicine, energy, biotechnology, information technology, and national security [105,109]. As illustrated in Fig. 3, nanoparticles have been utilized in various biomedical applications. Notably, their potential as a targeted delivery system for cancer cells represents a significant enhancement over existing breast cancer therapies and imaging tools [106,110].Fig. 3 Several applications of nanoparticles in biomedical field.

Fig. 3

Recent advancements in nanotechnology have allowed for the modification of nanostructures to selectively bind to tumor-specific receptors, thereby enhancing diagnostic accuracy and sensitivity [80]. Nanomaterial-based contrast agents, such as ultrasmall superparamagnetic iron oxide (USPIO) and superparamagnetic iron oxide (SPIO), exhibit prolonged circulation in the bloodstream and can target specific cell surface markers, leading to improved contrast properties in MRI imaging and facilitating reliable tumor diagnosis [59,94]. Tailored nanoparticles have shown promise in targeted chemotherapy, delivering drugs specifically to tumors while minimizing toxicity to surrounding normal cells, thereby enhancing the effectiveness of radiotherapy and improving treatment outcomes [111]. The modifiable characteristics of nanoparticles, including size, shape, charge, surface properties, and functionality, can be synergistically employed with precision medicine approaches to optimize patient stratification methods, indicating the potential of nanoparticles in the era of precision medicine [80,87,112]. Nano immunotherapies, utilizing nanomaterial-based formulations, have the potential to enhance the therapeutic benefits of immunotherapies by targeting the immunosuppressive tumor microenvironment and activating the immune system through interactions with other immune cells. Recent advancements in nanobiotechnology have sparked interest in utilizing nanomaterials for tumor immunotherapy due to their targeted drug delivery, controlled release at specific locations, surface functionalization capabilities, conjugated therapy potential, and low immunogenicity, resulting in effective immune system activation [87,113]. Specifically, tailored drug delivery methods involving a range of nanomaterials have revolutionized TAM related immunotherapies [93,114]. These nanomaterials may improve the efficacy of immunotherapies by targeting the immunosuppressive microenvironment, interacting with immune cells, and reducing off-target toxicity and immune-related adverse effects. Studies have shown that nanoparticles may trigger the repolarization of antiinflammatory M2 type macrophages towards a proinflammatory M1 phenotype, leading to tumor inhibition in several malignancies [14,92]. TAMs are further discovered to act as drug accumulation reservoirs, facilitating local delivery of nanotherapeutics to tumor cells and enhancing their efficacy by changing the spatial distribution of pharmacological chemicals within tumors. Notably, tumor macrophage uptake of nanoparticles is critical to generating therapeutically beneficial drug accumulation within tumors, as the elimination of macrophages significantly reduces nanoparticle deposition and renders the treatment ineffective [115]. TAM-targeting nanoimmunotherapies have become beneficial by combining the synergistic effects of TAMs and nanomaterials, and many macrophage-targeting nanomedicines have been developed in recent years.

11.1 Various nanomaterials for TAMs focused immunotherapy

As illustrated in Fig. 4, there are currently several types of nanoparticles (NPs) available for drug delivery in TAM-centered cancer immunotherapy [15,113,116]. Organic nanomaterials (such as lipids/liposomes, polymeric micelles, and polymeric NPs), inorganic nanomaterials (such as carbon based NPs, silicon-based NPs, and metal-based NPs such as gold, manganese, zinc, and iron) [15,87,117], as shown in Table 1.Fig. 4 Different types of nanoparticles (NPs) are used in drug delivery systems.

Fig. 4

Table 1 Advantages and disadvantages of various nanocarriers.

Table 1Nanocarrier	Classification	Advantages	Disadvantages	Ref.	
Silicon NPs	Inorganic	Biocompatible, nontoxic, photoluminescence, and highly adsorbent	Based on the size and dosage, it has the potential to induce cytotoxicity, oxidative stress, and DNA damage	[131,132]	
Carbon NPs	Inorganic	Unique optical, electrical, mechanical, thermal, chemical characteristics, and have antibacterial and antiinflammatory properties	Induce oxidative stress	[133,134]	
Ceramic NPs	Inorganic	CNs NPs have dielectric, optical, magnetism characteristics and show multiple bioactive characteristics, including antibacterial activity, tissue regeneration, and wound healing	Cell damage, genotoxicity and induce oxidative stress	[[135], [136], [137]]	
Lipid NPs	Organic	Low toxicity, biocompatibility, and excellent control of drug release	Minimal drug loading capacity	[138]	
Polymeric micelles	Organic	High stability in physiological media, the ability to decorate surfaces with targeted ligands, and Increased permeability and retention effect for passive tumor targeting	Synthetic polymers may cause toxicity, and immunogenicity challenges	[139]	
Dendrimers	Organic	Highly branched, monodisperse, biocompatibility, high permeability, polyvalency, chemical stability, and low immunogenicity	Intrinsic toxicity	[140,141]	
Gold NPs	Metals	Remarkable optical, electrical, and photothermal characteristics for imaging and targeting therapy	The tendency to aggregate results in a decrease in bioavailability and Potential cytotoxicity and genotoxicity at high dosages	[142]	
Metal oxide NPs	Metals	Superparamagnetic characteristics enable magnetic targeting and MRI imaging	Potential toxicity and induces oxidative stress in cells and organs	[143,144]	

These NP formulations can efficiently carry and deliver drugs to TAMs. As previously mentioned, NPs have a higher tendency for internalization by TAMs, making them suitable drug carriers for macrophages for targeting tumor cells. Furthermore, when NPs are engineered to target and phagocytosis TAMs, the physical properties of NPs, such as size, charge, and shape, can influence the phagocytosis response. Therefore, the selection of appropriate carrier materials is crucial for the success of TAM targeting immunotherapy.

11.1.1 Inorganic nanocarriers for breast cancer therapy

Inorganic nanocarriers are essential in breast cancer treatment as they effectively manipulate the tumor microenvironment, which includes their ability to target TAMs [118]. Nanocarriers, such as silicon, carbon-based, ceramic, and up-conversion nanoparticles, have demonstrated notable benefits in photodynamic therapy (PDT) for breast cancer treatment. These benefits include improved solubility, biodistribution, and intercellular penetration, resulting in more efficient destruction of cancer cells [119]. In addition, inorganic nanoparticles have been employed in drug delivery systems to enhance targeting, mitigate tumor resistance, and augment the effectiveness of chemotherapeutic drugs such as doxorubicin in breast cancer chemoimmunotherapy [118,120]. Incorporating inorganic nanocarriers shows great promise in addressing immunosuppressive circumstances in the tumor microenvironment and augmenting the antitumor immune response. Consequently, they serve as effective tools for combating breast cancer.

11.1.2 Organic nanocarriers for breast cancer therapy

Organic nanocarriers with specific physicochemical features and surface modifications, such as lipid-based nanocarriers, polymeric micelles, dendrimers, and polymeric nanoparticles, can be engineered to penetrate solid tumors and target TAMs [114,[121], [122], [123]]. To enhance the therapeutic efficiency of breast cancer treatments by targeting TAMs, polymer-based nanocarriers such as dendrimers, polymeric nanoparticles, and polymer micelles have grown in recent years [122]. To improve TAM targeting, scientists can change the surface of liposomes and liquid crystalline nanoparticles (LCNPs) by adding cationic chitosan and anionic hyaluronic acid. Researchers found that tamoxifen and resveratrol-loaded TAM targeting LCNPs significantly reduced the growth of breast cancer cells [122].For instance, docetaxel-based self-emulsified drug delivery systems (SEDDS) have shown promise in identifying and removing TAMs from breast cancer cells [14,122]. Overall, the incorporation of therapeutic medicines into organic nanocarriers. This nanoformulation can enhance breast cancer patient s' treatment efficacy. Organic nanocarriers for TAM targeted breast cancer treatment have promise but require more study and clinical trials to confirm their efficacy.

11.1.3 Metal nanocarriers for breast cancer therapy

Metal nanocarriers have a vital role in breast cancer treatment, particularly to target TAMs. Nanocarriers, such as gold nanoparticles and metal oxide nanoparticles, possess distinct characteristics that improve the distribution of drugs and the effectiveness of therapy in the treatment of breast cancer [124,125]. Functionalizing them with biomolecules enhances their selectivity against cancer cells, triggers cytotoxic effects through ROS production and apoptosis, and improves the absorption of drugs by breast cancer cells. As a result, their cytotoxicity significantly increases compared to free medicines [126,127]. Evidence suggests that gold nanoparticles may be useful in the delivery of chemotherapy drugs such as DOX to patients undergoing treatment for breast cancer [128]. Another approach is based on applying iron oxide nanoparticles; researchers were able to construct designed nanocomplexes that limit the polarization of TAMs to the protumor M2 type, presenting a unique approach to TAM treatment in breast cancer [129]. To further enhance anticancer effects through alterations to the tumor microenvironment, metal complexes integrated into dual target nanotherapeutics have demonstrated remarkable cytotoxic and immunomodulatory capabilities [130]. Moreover, metal nanocarriers can modify the tumor microenvironment, reorient macrophages to enhance the immune response against tumors, and specifically inhibit the growth of breast tumors. These properties make them highly promising in the battle against breast cancer, particularly in dealing with TAMs [127].

12 Nanotechnology approaches of TAM specific drug delivery for breast cancer

Nanomaterials can be designed to deliver drugs into the tumor region via passive or active mechanisms. Active targeting requires binding components such as antibodies and peptides to receptor structures expressed in the target region [145]. In passive targeting, the drug carrier complex generates circulation via the circulation and is driven to the target site by affinity or binding regulated by variables such as pH, molecular site, temperature, and shape [14]. The principal targets of the body are cell membrane receptors, lipid membrane components, and cell surface antigens or proteins. Nanotechnology-enhanced drug delivery systems are currently being developed to prevent and treat malignancies [146]. Drug delivery system (DDS) advancements have resulted in improved properties such as reduced particle size, higher permeability, increased solubility, and improved effectiveness [147]. These enhancements have made drug delivery more selective, precise, and focused, effectively addressing challenges associated with certain treatment classes [148,149]. Numerous therapeutic approaches and conventional diagnostic strategies have been investigated to improve accuracy in diagnosis and drug specificity with the recent development of nanomedicine, drug discovery and design, and drug delivery systems [148]. For example, novel pharmaceutical delivery systems are being investigated with a view to ensuring targeted action, minimizing toxicity, and enhancing bioavailability [148]. Despite these advances, there are still challenges with drug delivery, such as targeting drugs to tumor locations and achieving continuous release through a specified time [147]. To overcome these concerns, researchers are focused on the development of multifunctional delivery systems and the combination of diverse drug delivery mechanisms to ensure optimal drug distribution and desired therapeutic outcomes [148]. Nanodrug delivery system based nanoparticles have altered the landscape of conventional cancer therapy [145]. TAMs have been targeted using nanodrug delivery systems to enhance the efficacy of breast cancer treatment [43,150]. TAMs can be cured via nucleic acid therapies delivered by nanodrug delivery systems (NDDSs) with a variety of designs [151]. Recent research has revealed that nanodrug delivery methods play a crucial role in TAM-based immunotherapy [152,153]. These systems deliver pharmaceuticals or active chemicals to tumor locations, either directly or indirectly inducing immune responses, as shown in Table 2 [154].Table 2 Drug delivery systems targeting the site of tumor without affecting normal cells.

Table 2Nanocarrier	Therapeutic agent	Advantages	Model	Reference	
Pegylated polyethylenimine and zymosan complex	DOX and Zymosan	- Reducing toxicity

- Promote antiangiogenesis

	In vitro & In vivo	[112]	
Hyaluronic acid modified Fe3O4 NPs	DOX	- Enhance cell phagocytosis -Upregulate M1 macrophage

- Downregulate M2 macrophage

	In vitro & In vivo	[155]	
LNs	DHA and PTX	- Reprogramming

	In vitro & In vivo	[64]	
Cationic polymeric NPs	siCCR2	- Block CCR2 expression in monocytes

- Reduce TAMs abundance

	In vitro & In vivo	[156]	
Liposome	Zol	- Selective targeting

- Repolarization of TAMs

	In vitro & In vivo	[157]	
PLGA	Imiquimod and DOX	- Reprogramming

	In vitro	[158]	
PLGA Polymeric NPs	PTX and Trastuzumab	- Improve solubility

- Enhance stability

- Enhance bioavailability with no issue of hypersensitivity reactions

- Blocking the pgp efflux transport protein system

	In vitro	[159]	
Micelles	DOX	- Enhanced cell apoptosis

	In vitro & In vivo	[58]	
Chitosan	Oxalipaltin	- Chemically stable

- Biodegradable and noncytotoxic

	In vitro	[160]	
PLGA: Poly(lactic-co-glycolic acid); NPs: Nanoparticles; LNs: Lipid nanoemulsions; DOX: Doxorubicin; DHA: Docosahexaenoic acid; PTX: Paclitaxel; siCCR2:Small Interfering and Zol: Zoledronic Acid.

TAMs play critical roles in suppressing the immune system in metastatic breast cancer, and nanodrug delivery devices have been demonstrated to benefit metastatic breast cancer therapy [161]. To improve their selectivity for TAMs, nanoparticles can be functionalized with targeted ligands [105]. Some nanoformulations have been designed to selectively deliver lower dosages of tamoxifen to breast tumors while maintaining high accuracy and reducing off target adverse effects [150]. For the treatment of breast cancer, injectable nanodrug delivery devices have been developed [105,162]. These systems have the potential to increase drug stability, blood circulation time, aqueous solubility, controlled release, and other properties [105,149]. Combination therapies can target various components in TME, including TAMs, the tumor extracellular matrix, the tumor vasculature, and immunosuppressive components [105,149]. Overall, studies on TAM targeting nanodrug delivery systems for breast cancer treatment focus on optimizing drug delivery to TAMs, improving antitumor efficacy, and reducing immunosuppression by modifying the immunosuppressive environment. These approaches offer various advantages and could potentially be used to treat breast cancer.

13 Nanocarriers deliver plant-derived therapeutics to modulate TAM

Researchers have explored several plant-derived compounds, such as curcumin, genistein, and resveratrol, for their potential as antineoplastic agents and for loading them into nanocarriers to target TAMs in breast cancer. Curcumin, a polyphenolic component extracted from turmeric, possesses antiinflammatory and anticancer characteristics. Loading it into nanoparticles can improve its bioavailability and targeting capabilities for TAMs [101,150]. Research has shown that curcumin can effectively inhibit the growth of cancer cells at every stage, from initiation to progression, both in vitro and in vivo [163]. Because it forms bonds with the fatty acyl chains of cell membrane lipids through hydrophobic interactions and hydrogen bonding, it can't get through biological membranes. As a result, curcumin levels in the cytoplasm remain extremely low. A potential solution to these challenges and an increase in bioavailability is curcumin nanosystems, which enhance curcumin's therapeutic properties [163]. Also, genistein is an attractive candidate for anticancer treatment because of its ability to trigger cell cycle arrest, apoptosis, and angiogenesis inhibition. Additionally, it controls epigenetic regulation and modulates multiple signaling pathways, such as the PI3K/AKT and MAPK (ERK1/2) pathways [164,165]. Loading genistein into nanoparticles can improve its bioavailability and targeting capabilities for TAMs. Because of its poor bioavailability and metabolism, genistein may have its limitations circumvented by this approach [166]. Substantial research has also explored the potential anticancer effects of resveratrol, a polyphenolic compound present in many plants [107]. We can load resveratrol into nanoparticles to improve its bioavailability and targeting capabilities for TAMs [9]. Researchers have shown that resveratrol-loaded nanoparticles inhibit the proliferation of breast cancer cells in vitro. In vivo investigations have demonstrated the ability of these nanoparticles to target TAMs and suppress tumor growth [167]. Combining nanosystems with resveratrol enhances water solubility, stability, and permeability across biological membranes, leading to an enhanced permeation and retention effect (EPR) at tumor sites [167,168]. Overall Different nanocarriers, such as liposomes, polymeric nanoparticles, or metallic nanoparticles, can encapsulate plant-derived compounds to enhance their effectiveness and ability to target TAMs in breast cancer.

14 Preclinical studies evaluating the potential of nanomedicines for targeting TAMs

Preclinical studies have revealed remarkable progress in the fabrication of TAM targeted nanomedicines for cancer immunotherapy [3,169]. These nanomedicines propose to overcome challenges associated with TAM induced tumor immunosuppression and increase therapeutic specificity and efficacy [36]. As shown in Table 3, numerous types of nanomaterials have been investigated, including multifunctional nanocarriers with high solubility, cell specific delivery, and controlled release of therapeutic payloads [156,170].Table 3 Recent strategies for TAM targeted nanomedicines in preclinical studies for BC therapy.

Table 3Nanocarrier	Target	Therapeutic agent	Effect	Reference	
β-Cyclodextrin	TLR7	R848	Re-Education	[171]	
Liposome	STING	cGAMP	Re-Education	[104]	
PLGA	CD44	Docetaxel	Improved in vitro cellular uptake and cytotoxicity	[172]	
Liposome	LHRHR	Mitoxantrone	Suppress tumor growth	[173]	
PD-L1 Anti-body	PD-L1	TLR agonist	Re-Education	[99]	
7C1 nanoparticle	CX3CL1 mRNA	CX3CL1 siRNA	Recruitment Block	[174]	
Polymeric micelles	Mannose receptor on TAM	Imiquimod (R837) and DOX	Activation of macrophage
Suppress tumor growth	[175]	
Liposome	PD-1	DOX	Suppress tumor growth	[176]	
PLGA: Poly(lactic-co-glycolic acid); DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane; PC: Phosphatidylcholine; TLR7: Toll-like receptor 7; STING: Stimulator of interferon genes; LHRHR: Luteinizing hormone-releasing hormone; PD-1: Programmed cell death protein 1; cGAMP: and Cyclic guanosine monophosphate-adenosine monophosphate.

Preclinical trials have been carried out to investigate the use of nanotechnology for macrophage targeting in diseases that include various types of cancer and inflammatory disorders [153]. An instance of ongoing clinical research focuses on examining the effectiveness of liposomal nanoparticles containing a chemotherapy drug as a tool for TAM targeting in solid tumors [120,177]. While preclinical models have shown promising results, there is still a requirement for enhancing nanoparticle design and utilizing preclinical models that closely mimic the human environment to validate their effectiveness as precision medicine.

15 Conclusion

In conclusion, this review highlights the pivotal role of tumor associated macrophages in breast cancer progression. TAMs are the predominant immune cells in cancerous growths, making up around half of the total immune cell population infiltrating the tumor. These are divided into two separate subgroups, TAM1 and TAM2, which have diverse roles and characteristics. TAM1 displays a proinflammatory phenotype and plays a role in phagocytosis, identification of cancer cells, and initiation of tumor cell killing. The organism generates proinflammatory cytokines and exhibits major histocompatibility complex class II, enhancing antigen display. Conversely, TAM2 plays a role in diminishing inflammation and encouraging fibrosis, which establishes it as the prevailing subtype inside the tumor microenvironment. TAM2 has been linked to the promotion of tumor growth, invasion, and metastasis in breast cancer. An imbalance in the populations of TAM1 and TAM2 might result in the development of pathogenic conditions, such as chronic inflammatory diseases or immune suppression. Hence, approaches aimed at inducing repolarization of TAMs towards the TAM1 phenotype have demonstrated potential in suppressing tumor proliferation. The review emphasizes the promising potential of targeting TAMs for innovative breast cancer therapies, particularly through nanomedicine approaches. Nanotechnology provides potential opportunities for TAMs in the treatment of breast cancer. Nanocarriers, including inorganic, organic, and metals, have been employed to transport chemotherapeutic drugs and gene treatments to breast tumor cells. This approach has resulted in enhanced treatment efficacy and decreased drug resistance. In addition, researchers have created nanocarriers that can react to specific stimuli and modify the tumor microenvironment. These nanocarriers aim to improve the immune system responses to tumors and change the behavior of macrophages. This review underscores the importance of continuing research into TAMs as a means to improve breast cancer treatment outcomes and enhance antitumor immune responses.

Consent for publication

All the authors read and agreed to publish this article.

Funding

This work was supported by the 10.13039/501100022230 Deanship of Scientific Research , Vice Presidency for Graduate Studies and Scientific Research, 10.13039/501100020912 King Faisal University, Saudi Arabia [Grant No. KFU241725 ].

Data availability

Data included in article/referenced in article.

CRediT authorship contribution statement

Ghazala Muteeb: Writing – review & editing, Writing – original draft, Conceptualization. Doaa S.R. Khafaga: Writing – review & editing, Writing – original draft, Conceptualization. Manar T. El-Morsy: Writing – review & editing, Writing – original draft. Mohd Farhan: Writing – review & editing, Writing – original draft. Mohammad Aatif: Writing – review & editing, Supervision, Project administration, Funding acquisition, Conceptualization. Mohamed Hosney: Writing – review & editing, Writing – original draft, Supervision, Project administration, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

Not applicable.
==== Refs
References

1 Huang Xinqun Cao Jingsong Zu X. Tumor‐associated macrophages: an important player in breast cancer progression Thoracic Cancer 13 2022 269 276 10.1111/1759-7714.14268 34914196
2 Chen F. Chen J. Yang L. Liu J. Zhang X. Zhang Y. Tu Q. Yin D. Lin D. Wong P.-P. Huang D. Xing Y. Zhao J. Li M. Liu Q. Su F. Su S. Song E. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells Nat. Cell Biol. 21 2019 498 510 10.1038/s41556-019-0299-0 30936474
3 Wei X. Wang J. Liang M. Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy Theranostics 12 2022 7821 7852 10.7150/thno.78572 36451865
4 Zhang Y. Chen Y. Li J. Zhu X. Liu Y. Wang X. Wang H. Yao Y. Gao Y. Chen Z. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages ACS Appl. Mater. Interfaces 13 2021 24442 24452 10.1021/acsami.1c01453 34008947
5 Clark N.M. Bos P.D. Tumor-associated macrophage isolation and in vivo analysis of their tumor-promoting activity López-Soto A. Folgueras A.R. Cancer Immunosurveillance 2019 Springer New York New York, NY 151 160 10.1007/978-1-4939-8885-3_10
6 Biswas S.K. Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat. Immunol. 11 2010 889 896 10.1038/ni.1937 20856220
7 Genard G. Lucas S. Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies Front. Immunol. 8 2017 828 10.3389/fimmu.2017.00828 28769933
8 Mantovani A. Longo D.L. Macrophage checkpoint blockade in cancer — back to the future N. Engl. J. Med. 379 2018 1777 1779 10.1056/NEJMe1811699 30380398
9 Mantovani A. Schioppa T. Porta C. Allavena P. Sica A. Role of tumor-associated macrophages in tumor progression and invasion Cancer Metastasis Rev. 25 2006 315 322 10.1007/s10555-006-9001-7 16967326
10 Pérez S. Rius-Pérez S. Macrophage polarization and reprogramming in acute inflammation: a redox perspective Antioxidants 11 2022 1394 10.3390/antiox11071394 35883885
11 Liu L. Wang Y. Guo X. Zhao J. Zhou S. A biomimetic polymer magnetic nanocarrier polarizing tumor‐associated macrophages for potentiating immunotherapy Small 16 2020 2003543 10.1002/smll.202003543
12 Jézéquel P. Kerdraon O. Hondermarck H. Guérin-Charbonnel C. Lasla H. Gouraud W. Canon J.-L. Gombos A. Dalenc F. Delaloge S. Lemonnier J. Loussouarn D. Verrièle V. Campone M. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications Breast Cancer Res. 21 2019 65 10.1186/s13058-019-1148-6 31101122
13 Zahavi D. Weiner L. Monoclonal antibodies in cancer therapy Antibodies 9 2020 34 10.3390/antib9030034 32698317
14 Alhalmi A. Beg S. Almalki W.H. Alghamdi S. Kohli K. Recent advances in nanotechnology-based targeted therapeutics for breast CancerManagement CDM 23 2022 587 602 10.2174/1389200223666220514151110
15 Zhao W. Hu X. Li W. Li R. Chen J. Zhou L. Qiang S. Wu W. Shi S. Dong C. M2‐Like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy Small 17 2021 2007051 10.1002/smll.202007051
16 Wang R. Kumar P. Reda M. Wallstrum A.G. Crumrine N.A. Ngamcherdtrakul W. Yantasee W. Nanotechnology applications in breast cancer immunotherapy Small 2023 2308639 10.1002/smll.202308639
17 Tung B.T. Quynh C.T.X. Hong N.K. Nanotechnology applications in breast cancer Pandurangan A.K. Anandasadagopan S.K. Alhumaydhi F.A. Advances in Medical Diagnosis, Treatment, and Care 2022 IGI Global 442 465 10.4018/978-1-7998-9258-8.ch020
18 Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis Nat. Rev. Cancer 4 2004 71 78 10.1038/nrc1256 14708027
19 Abdel-Razeq H. Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives Front. Oncol. 13 2023 1265197 10.3389/fonc.2023.1265197
20 Lan H.-R. Chen M. Yao S.-Y. Chen J.-X. Jin K.-T. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview Front. Immunol. 14 2023 1266450 10.3389/fimmu.2023.1266450
21 Roheel A. Khan A. Anwar F. Akbar Z. Akhtar M.F. Imran Khan M. Sohail M.F. Ahmad R. Global epidemiology of breast cancer based on risk factors: a systematic review Front. Oncol. 13 2023 1240098 10.3389/fonc.2023.1240098
22 Sheikhpour E. Noorbakhsh P. Foroughi E. Farahnak S. Nasiri R. Neamatzadeh H. A survey on the role of interleukin-10 in breast cancer: a narrative Rep Biochem Mol Biol 7 2018 30 37 30324115
23 ChÃ¡vez-GalÃ¡n L. Olleros M.L. Vesin D. Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages Front. Immunol. 6 2015 10.3389/fimmu.2015.00263
24 Ge Z. Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy Front. Oncol. 10 2020 590941 10.3389/fonc.2020.590941
25 Bergenfelz C. Medrek C. Ekström E. Jirström K. Janols H. Wullt M. Bredberg A. Leandersson K. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients J. Immunol. 188 2012 5448 5458 10.4049/jimmunol.1103378 22547701
26 Reddy J.P. Atkinson R.L. Larson R. Burks J.K. Smith D. Debeb B.G. Ruffell B. Creighton C.J. Bambhroliya A. Reuben J.M. Van Laere S.J. Krishnamurthy S. Symmans W.F. Brewster A.M. Woodward W.A. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer Breast Cancer Res. Treat. 171 2018 283 293 10.1007/s10549-018-4835-6 29858753
27 Yang W. Liu W. Hu N. Li C. The role of macrophages in cancer immunity Rezaei N. Handbook of Cancer and Immunology 2022 Springer International Publishing Cham 1 26 10.1007/978-3-030-80962-1_19-1
28 Qiu S.-Q. Waaijer S.J.H. Zwager M.C. De Vries E.G.E. Van Der Vegt B. Schröder C.P. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 70 2018 178 189 10.1016/j.ctrv.2018.08.010 30227299
29 Qian B.-Z. Pollard J.W. Macrophage diversity enhances tumor progression and metastasis Cell 141 2010 39 51 10.1016/j.cell.2010.03.014 20371344
30 Anfray Ummarino Andón Allavena Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses Cells 9 2019 46 10.3390/cells9010046 31878087
31 Mendoza-Reinoso V. McCauley L.K. Fournier P.G.J. Contribution of macrophages and T cells in skeletal metastasis Cancers 12 2020 1014 10.3390/cancers12041014 32326073
32 DeSantis C.E. Ma J. Goding Sauer A. Newman L.A. Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state, CA A Cancer J Clinicians 67 2017 439 448 10.3322/caac.21412
33 Zhuang X. Wang J. Correlations of MRP1 gene with serum TGF-β1 and IL-8 in breast cancer patients during chemotherapy J BUON 23 2018 1302 1308 30570851
34 Advani R. Flinn I. Popplewell L. Forero A. Bartlett N.L. Ghosh N. Kline J. Roschewski M. LaCasce A. Collins G.P. Tran T. Lynn J. Chen J.Y. Volkmer J.-P. Agoram B. Huang J. Majeti R. Weissman I.L. Takimoto C.H. Chao M.P. Smith S.M. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma N. Engl. J. Med. 379 2018 1711 1721 10.1056/NEJMoa1807315 30380386
35 Wang J. Li D. Cang H. Guo B. Crosstalk between cancer and immune cells: role of tumor‐associated macrophages in the tumor microenvironment Cancer Med. 8 2019 4709 4721 10.1002/cam4.2327 31222971
36 Zhou H. Jia W. Lu L. Han R. MicroRNAs with multiple targets of immune checkpoints, as a potential sensitizer for immune checkpoint inhibitors in breast cancer treatment Cancers 15 2023 824 10.3390/cancers15030824 36765782
37 Gholamin S. Mitra S.S. Feroze A.H. Liu J. Kahn S.A. Zhang M. Esparza R. Richard C. Ramaswamy V. Remke M. Volkmer A.K. Willingham S. Ponnuswami A. McCarty A. Lovelace P. Storm T.A. Schubert S. Hutter G. Narayanan C. Chu P. Raabe E.H. Harsh G. Taylor M.D. Monje M. Cho Y.-J. Majeti R. Volkmer J.P. Fisher P.G. Grant G. Steinberg G.K. Vogel H. Edwards M. Weissman I.L. Cheshier S.H. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors Sci. Transl. Med. 9 2017 eaaf2968 10.1126/scitranslmed.aaf2968
38 Mahlbacher G. Curtis L.T. Lowengrub J. Frieboes H.B. Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment J. Immunotherapy Cancer 6 2018 10 10.1186/s40425-017-0313-7
39 Cheng N. Watkins-Schulz R. Junkins R.D. David C.N. Johnson B.M. Montgomery S.A. Peine K.J. Darr D.B. Yuan H. McKinnon K.P. Liu Q. Miao L. Huang L. Bachelder E.M. Ainslie K.M. Ting J.P.-Y. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer JCI Insight 3 2018 e120638 10.1172/jci.insight.120638
40 Xie L. Yang Y. Meng J. Wen T. Liu J. Xu H. Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression Int. J. Biol. Macromol. 123 2019 1012 1019 10.1016/j.ijbiomac.2018.11.089 30439425
41 Prasad C.P. Manchanda M. Mohapatra P. Andersson T. WNT5A as a therapeutic target in breast cancer Cancer Metastasis Rev. 37 2018 767 778 10.1007/s10555-018-9760-y 30171384
42 Solinas G. Germano G. Mantovani A. Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation J. Leukoc. Biol. 86 2009 1065 1073 10.1189/jlb.0609385 19741157
43 Sawa-Wejksza K. Kandefer-Szerszeń M. Tumor-associated macrophages as target for antitumor therapy Arch. Immunol. Ther. Exp. 66 2018 97 111 10.1007/s00005-017-0480-8
44 Pan Y. Yu Y. Wang X. Zhang T. Tumor-associated macrophages in tumor immunity Front. Immunol. 11 2020 583084 10.3389/fimmu.2020.583084
45 Engblom C. Pfirschke C. Pittet M.J. The role of myeloid cells in cancer therapies Nat. Rev. Cancer 16 2016 447 462 10.1038/nrc.2016.54 27339708
46 Rivera L.B. Bergers G. Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity Cancer Cell 24 2013 687 689 10.1016/j.ccr.2013.11.014 24332035
47 Mehta A.K. Kadel S. Townsend M.G. Oliwa M. Guerriero J.L. Macrophage biology and mechanisms of immune suppression in breast cancer Front. Immunol. 12 2021 643771 10.3389/fimmu.2021.643771
48 Boutilier A.J. Elsawa S.F. Macrophage polarization states in the tumor microenvironment IJMS 22 2021 6995 10.3390/ijms22136995 34209703
49 Pernot S. Evrard S. Khatib A.-M. The give-and-take interaction between the tumor microenvironment and immune cells regulating tumor progression and repression Front. Immunol. 13 2022 850856 10.3389/fimmu.2022.850856
50 Morandi A. Barbetti V. Riverso M. Dello Sbarba P. Rovida E. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines PLoS One 6 2011 e27450 10.1371/journal.pone.0027450
51 Cancers | Free Full-Text | Targeting Tumor-Associated Macrophages in Cancer Immunotherapy, (n.d.). https://www.mdpi.com/2072-6694/13/21/5318 (accessed June 24, 2024).
52 Giordano C. La Camera G. Gelsomino L. Barone I. Bonofiglio D. Andò S. Catalano S. The biology of exosomes in breast cancer progression: dissemination, immune evasion and metastatic colonization Cancers 12 2020 2179 10.3390/cancers12082179 32764376
53 Nabet B.Y. Qiu Y. Shabason J.E. Wu T.J. Yoon T. Kim B.C. Benci J.L. DeMichele A.M. Tchou J. Marcotrigiano J. Minn A.J. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer Cell 170 2017 352 366.e13 10.1016/j.cell.2017.06.031 28709002
54 Devhare P.B. Ray R.B. Extracellular vesicles: novel mediator for cell to cell communications in liver pathogenesis Mol. Aspect. Med. 60 2018 115 122 10.1016/j.mam.2017.11.001
55 Wang S. Liu X. Chen S. Liu Z. Zhang X. Liang X.-J. Li L. Regulation of Ca 2+ signaling for drug-resistant breast cancer therapy with mesoporous silica nanocapsule encapsulated doxorubicin/siRNA cocktail ACS Nano 13 2019 274 283 10.1021/acsnano.8b05639 30566319
56 Mukhtar R.A. Nseyo O. Campbell M.J. Esserman L.J. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics Expert Rev. Mol. Diagn. 11 2011 91 100 10.1586/erm.10.97 21171924
57 Rezaei S. Azarpira N. Koohpeyma F. Yousefi R. Doaei S. Heidari M. Gholamalizadeh M. Haghshenas M. Mazloom Z. Evaluation of morphology and angiogenesis of breast cancer in BALB/c mice using trypsin inhibitor from Cucumis melo seeds vitro and in vivo study, Wo 26 2022 204 219 10.5114/wo.2022.120700
58 Chen L. Cao L. Zhan M. Li J. Wang D. Laurent R. Mignani S. Caminade A.-M. Majoral J.-P. Shi X. Engineered stable bioactive per Se amphiphilic phosphorus dendron nanomicelles as a highly efficient drug delivery system to take down breast cancer in vivo Biomacromolecules 23 2022 2827 2837 10.1021/acs.biomac.2c00197 35694854
59 Liu J. Zhang N. Li Q. Zhang W. Ke F. Leng Q. Wang H. Chen J. Wang H. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice PLoS One 6 2011 e19495 10.1371/journal.pone.0019495
60 Mempel T.R. Lill J.K. Altenburger L.M. How chemokines organize the tumour microenvironment Nat. Rev. Cancer 24 2024 28 50 10.1038/s41568-023-00635-w 38066335
61 Groblewska M. Litman-Zawadzka A. Mroczko B. The role of selected chemokines and their receptors in the development of gliomas Int. J. Mol. Sci. 21 2020 3704 10.3390/ijms21103704 32456359
62 Chen J. Yao Y. Gong C. Yu F. Su S. Chen J. Liu B. Deng H. Wang F. Lin L. Yao H. Su F. Anderson K.S. Liu Q. Ewen M.E. Yao X. Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3 Cancer Cell 19 2011 541 555 10.1016/j.ccr.2011.02.006 21481794
63 Drouillard D. Craig B.T. Dwinell M.B. Physiology of chemokines in the cancer microenvironment American Journal of Physiology-Cell Physiology 324 2023 C167 C182 10.1152/ajpcell.00151.2022 36317799
64 Li B. Tan T. Chu W. Zhang Y. Ye Y. Wang S. Qin Y. Tang J. Cao X. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy Drug Deliv. 29 2022 75 88 10.1080/10717544.2021.2018523 34964421
65 Behl T. Kumar A. Vishakha Sehgal A. Singh S. Sharma N. Yadav S. Rashid S. Ali N. Ahmed A.S. Vargas-De-La-Cruz C. Bungau S.G. Khan H. Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer Int. J. Biol. Macromol. 253 2023 126595 10.1016/j.ijbiomac.2023.126595
66 Adyani S.M. Rashidzadeh H. Behdani M. Tabatabaei Rezaei S.J. Ramazani A. In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate Iranian Journal of Basic Medical Sciences 25 2022 10.22038/ijbms.2022.67038.14701
67 Singh Tuli H. Nanotherapeutics in Cancer: Materials, Diagnostics, and Clinical Applications first ed. 2022 Jenny Stanford Publishing New York 10.1201/9781003334538
68 Lievense L.A. Cornelissen R. Bezemer K. Kaijen-Lambers M.E.H. Hegmans J.P.J.J. Aerts J.G.J.V. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression J. Thorac. Oncol. 11 2016 1755 1764 10.1016/j.jtho.2016.06.021 27418106
69 Curiel T.J. Coukos G. Zou L. Alvarez X. Cheng P. Mottram P. Evdemon-Hogan M. Conejo-Garcia J.R. Zhang L. Burow M. Zhu Y. Wei S. Kryczek I. Daniel B. Gordon A. Myers L. Lackner A. Disis M.L. Knutson K.L. Chen L. Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949 10.1038/nm1093 15322536
70 Ji X. Huang X. Li C. Guan N. Pan T. Dong J. Li L. Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells Cell Commun. Signal. 21 2023 197 10.1186/s12964-023-01208-y 37542283
71 Khan S.U. Khan M.U. Azhar Ud Din M. Khan I.M. Khan M.I. Bungau S. Hassan S.S.U. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy Front. Immunol. 14 2023 1166487 10.3389/fimmu.2023.1166487
72 Wang H. Vo T. Hajar A. Li S. Chen X. Parissenti A.M. Brindley D.N. Wang Z. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells BMC Cancer 14 2014 37 10.1186/1471-2407-14-37 24447372
73 Cox A.D. Fesik S.W. Kimmelman A.C. Luo J. Der C.J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13 2014 828 851 10.1038/nrd4389 25323927
74 De Bessa-Garcia S.A. Nagai M.A. Involvement of par-4 in breast cancer Rangnekar V.M. Tumor Suppressor Par-4 2021 Springer International Publishing Cham 113 131 10.1007/978-3-030-80558-6_7
75 Hebbar N. Shrestha-Bhattarai T. Rangnekar V.M. Cancer-selective apoptosis by tumor suppressor par-4 Grimm S. Anticancer Genes 2014 Springer London 155 166 10.1007/978-1-4471-6458-6_7
76 Pereira M.C. De Bessa-Garcia S.A. Burikhanov R. Pavanelli A.C. Antunes L. Rangnekar V.M. Nagai M.A. Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells Int. J. Oncol. 43 2013 531 538 10.3892/ijo.2013.1983 23760770
77 Uddin MdH. Azmi A.S. Mohammad R.M. Potential of PAR-4 as a therapeutic target for pancreatic cancer Rangnekar V.M. Tumor Suppressor Par-4: Role in Cancer and Other Diseases 2021 Springer International Publishing Cham 161 170 10.1007/978-3-030-80558-6_10
78 Townsend M.H. Shrestha G. Robison R.A. O'Neill K.L. The expansion of targetable biomarkers for CAR T cell therapy J. Exp. Clin. Cancer Res. 37 2018 163 10.1186/s13046-018-0817-0 30031396
79 Jeong H. Hwang I. Kang S.H. Shin H.C. Kwon S.Y. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer J Breast Cancer 22 2019 38 10.4048/jbc.2019.22.e5 30941232
80 Mitchell M.J. Billingsley M.M. Haley R.M. Wechsler M.E. Peppas N.A. Langer R. Engineering precision nanoparticles for drug delivery Nat. Rev. Drug Discov. 20 2021 101 124 10.1038/s41573-020-0090-8 33277608
81 Chen N.-N. Ma X.-D. Miao Z. Zhang X.-M. Han B.-Y. Almaamari A.A. Huang J.-M. Chen X.-Y. Liu Y.-J. Su S.-W. Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARγ and CaMKII signaling pathway Front. Pharmacol. 14 2023 1150861 10.3389/fphar.2023.1150861
82 Williams C.B. Yeh E.S. Soloff A.C. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy Npj Breast Cancer 2 2016 15025 10.1038/npjbcancer.2015.25
83 Rogers T.L. Holen I. Tumour macrophages as potential targets of bisphosphonates J. Transl. Med. 9 2011 177 10.1186/1479-5876-9-177 22005011
84 Seeta Rama Raju G. Benton L. Pavitra E. Yu J.S. Multifunctional nanoparticles: recent progress in cancer therapeutics Chem. Commun. 51 2015 13248 13259 10.1039/C5CC04643B
85 Min K.A. Maharjan P. Ham S. Shin M.C. Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy Arch Pharm. Res. (Seoul) 41 2018 594 616 10.1007/s12272-018-1038-y
86 Mabe N.W. Fox D.B. Lupo R. Decker A.E. Phelps S.N. Thompson J.W. Alvarez J.V. Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer J. Clin. Invest. 128 2018 4413 4428 10.1172/JCI99481 30148456
87 Zhao Z. Zheng L. Chen W. Weng W. Song J. Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives J. Hematol. Oncol. 12 2019 126 10.1186/s13045-019-0817-3 31779642
88 Gok Yavuz B. Gunaydin G. Gedik M.E. Kosemehmetoglu K. Karakoc D. Ozgur F. Guc D. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs Sci. Rep. 9 2019 3172 10.1038/s41598-019-39553-z 30816272
89 Kashfi K. Kannikal J. Nath N. Macrophage reprogramming and cancer therapeutics: role of iNOS-derived NO Cells 10 2021 3194 10.3390/cells10113194 34831416
90 Coscia M. Quaglino E. Iezzi M. Curcio C. Pantaleoni F. Riganti C. Holen I. Mönkkönen H. Boccadoro M. Forni G. Musiani P. Bosia A. Cavallo F. Massaia M. Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway J Cellular Molecular Medi 14 2010 2803 2815 10.1111/j.1582-4934.2009.00926.x
91 Osipov A. Saung M.T. Zheng L. Murphy A.G. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape J. Immunotherapy Cancer 7 2019 224 10.1186/s40425-019-0667-0
92 Aehnlich P. Powell R.M. Peeters M.J.W. Rahbech A. Thor Straten P. TAM receptor inhibition–implications for cancer and the immune system Cancers 13 2021 1195 10.3390/cancers13061195 33801886
93 Chamseddine A.N. Assi T. Mir O. Chouaib S. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach Pharmacology & Therapeutics 231 2022 107986 10.1016/j.pharmthera.2021.107986
94 Li M. Li M. Yang Y. Liu Y. Xie H. Yu Q. Tian L. Tang X. Ren K. Li J. Zhang Z. He Q. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy J. Contr. Release 321 2020 23 35 10.1016/j.jconrel.2020.02.011
95 Kang X. Huang Y. Wang H. Jadhav S. Yue Z. Tiwari A. Babu R. Tumor-associated macrophage targeting of nanomedicines in cancer therapy Pharmaceutics 16 2023 61 10.3390/pharmaceutics16010061 38258072
96 St-Cyr G. Penarroya D. Daniel L. Giguère H. Alkayyal A.A. Tai L.-H. Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs Front. Immunol. 13 2023 1071223 10.3389/fimmu.2022.1071223
97 Shinde S.S. Ahmed S. Malik J.A. Hani U. Khanam A. Ashraf Bhat F. Ahmad Mir S. Ghazwani M. Wahab S. Haider N. Almehizia A.A. Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment Biology 12 2023 467 10.3390/biology12030467 36979159
98 Haque S. Cook K. Sahay G. Sun C. RNA-based therapeutics: current developments in targeted molecular therapy of triple-negative breast cancer Pharmaceutics 13 2021 1694 10.3390/pharmaceutics13101694 34683988
99 Fan P. Xu K. Antibody-drug conjugates in breast cancer: marching from HER2-overexpression into HER2-low Biochim. Biophys. Acta Rev. Canc 1878 2023 188849 10.1016/j.bbcan.2022.188849
100 Goydel R.S. Rader C. Antibody-based cancer therapy Oncogene 40 2021 3655 3664 10.1038/s41388-021-01811-8 33947958
101 Xiao M. He J. Yin L. Chen X. Zu X. Shen Y. Tumor-associated macrophages: critical players in drug resistance of breast cancer Front. Immunol. 12 2021 799428 10.3389/fimmu.2021.799428
102 Yang C. He L. He P. Liu Y. Wang W. He Y. Du Y. Gao F. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway Med. Oncol. 32 2015 14 10.1007/s12032-014-0352-6
103 Wu T. Dai Y. Tumor microenvironment and therapeutic response Cancer Lett. 387 2017 61 68 10.1016/j.canlet.2016.01.043 26845449
104 Cheng N. Watkins-Schulz R. Junkins R.D. David C.N. Johnson B.M. Montgomery S.A. Peine K.J. Darr D.B. Yuan H. McKinnon K.P. Liu Q. Miao L. Huang L. Bachelder E.M. Ainslie K.M. Ting J.P.-Y. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer JCI Insight 3 2018 e120638 10.1172/jci.insight.120638 120638
105 Tagde P. Najda A. Nagpal K. Kulkarni G.T. Shah M. Ullah O. Balant S. Rahman MdH. Nanomedicine-based delivery strategies for breast cancer treatment and management IJMS 23 2022 2856 10.3390/ijms23052856 35269998
106 Palit S. Hussain C.M. Nanodevices applications and recent advancements in nanotechnology and the global pharmaceutical industry Nanomaterials in Diagnostic Tools and Devices 2020 Elsevier 395 415 10.1016/B978-0-12-817923-9.00014-6
107 Kumar A. Kurmi B.D. Singh A. Singh D. Potential role of resveratrol and its nano-formulation as anti-cancer agent Explor Target Antitumor Ther. 2022 643 658 10.37349/etat.2022.00105 36338523
108 Ferrari M. Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 2005 161 171 10.1038/nrc1566 15738981
109 Muteeb G. Nanotechnology—a light of hope for combating antibiotic resistance Microorganisms 11 2023 1489 10.3390/microorganisms11061489 37374990
110 Khafaga D.S.R. El-Khawaga A.M. Elfattah Mohammed R.A. Abdelhakim H.K. Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review Mol. Biol. Rep. 2023 10.1007/s11033-023-08823-5
111 Woodman C. Vundu G. George A. Wilson C.M. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer Semin. Cancer Biol. 69 2021 349 364 10.1016/j.semcancer.2020.02.009 32088362
112 Gu X. Gao Y. Wang P. Wang L. Peng H. He Y. Liu Y. Feng N. Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis J. Contr. Release 333 2021 374 390 10.1016/j.jconrel.2021.03.039
113 Shi J. Kantoff P.W. Wooster R. Farokhzad O.C. Cancer nanomedicine: progress, challenges and opportunities Nat. Rev. Cancer 17 2017 20 37 10.1038/nrc.2016.108 27834398
114 Ovais M. Guo M. Chen C. Tailoring nanomaterials for targeting tumor‐associated macrophages Adv. Mater. 31 2019 1808303 10.1002/adma.201808303
115 Miller M.A. Zheng Y.-R. Gadde S. Pfirschke C. Zope H. Engblom C. Kohler R.H. Iwamoto Y. Yang K.S. Askevold B. Kolishetti N. Pittet M. Lippard S.J. Farokhzad O.C. Weissleder R. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug Nat. Commun. 6 2015 8692 10.1038/ncomms9692 26503691
116 Shi Z. Zheng J. Tang W. Bai Y. Zhang L. Xuan Z. Sun H. Shao C. Multifunctional nanomaterials for ferroptotic cancer therapy Front. Chem. 10 2022 868630 10.3389/fchem.2022.868630
117 Kapitanova K.S. Naumenko V.A. Garanina A.S. Melnikov P.A. Abakumov M.A. Alieva I.B. Advances and challenges of nanoparticle-based macrophage reprogramming for cancer immunotherapy Biochemistry Moscow 84 2019 729 745 10.1134/S0006297919070058 31509725
118 Zang X. Song J. Yi X. Piyu J. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer J. Mater. Chem. B 10 2022 2019 2027 10.1039/D2TB00197G 35254372
119 Montaseri H. Kruger C.A. Abrahamse H. Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer Pharmaceutics 13 2021 296 10.3390/pharmaceutics13030296 33668307
120 Jiang Y. Jiang Z. Wang M. Ma L. Current understandings and clinical translation of nanomedicines for breast cancer therapy Adv. Drug Deliv. Rev. 180 2022 114034 10.1016/j.addr.2021.114034
121 Rafik S.T. Vaidya J.S. MacRobert A.J. Yaghini E. Organic nanodelivery systems as a new platform in the management of breast cancer: a comprehensive review from preclinical to clinical studies J. Clin. Med. 12 2023 2648 10.3390/jcm12072648 37048731
122 Dasari N. Guntuku G.S. Pindiprolu S.K.S.S. Targeting triple negative breast cancer stem cells using nanocarriers Discover Nano 19 2024 41 10.1186/s11671-024-03985-y 38453756
123 Singh S. Sharma N. Zahoor I. Behl T. Antil A. Gupta S. Anwer M.K. Mohan S. Bungau S.G. Decrypting the potential of nanotechnology-based approaches as cutting-edge for management of hyperpigmentation disorder Molecules 28 2023 220 10.3390/molecules28010220
124 (Nano)platforms in Breast Cancer Therapy: Drug/gene Delivery, Advanced Nanocarriers and Immunotherapy - Ashrafizadeh - 2023 - Medicinal Research Reviews - Wiley Online Library, (n.d.). https://onlinelibrary.wiley.com/doi/10.1002/med.21971 (accessed June 24, 2024).
125 A-Kadhim M.M.-H. Kelkawi A.H.A. The role of gold nanoparticles/Au-PEG-PAMAM as drug delivery system for treatment of breast cancer Biomedicine and Chemical Sciences 2 2023 76 82 10.48112/bcs.v2i2.456
126 Subhan M.A. Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics RSC Adv. 12 2022 32956 32978 10.1039/D2RA02005J 36425155
127 Villalobos Gutiérrez P.T. Muñoz Carrillo J.L. Sandoval Salazar C. Viveros Paredes J.M. Gutiérrez Coronado O. Functionalized metal nanoparticles in cancer therapy Pharmaceutics 15 2023 1932 10.3390/pharmaceutics15071932 37514119
128 Faid A.H. Shouman S.A. Badr Y.A. Sharaky M. Enhanced cytotoxic effect of doxorubicin conjugated gold nanoparticles on breast cancer model BMC Chemistry 16 2022 90 10.1186/s13065-022-00889-9 36352463
129 Tian K. Feng R. Wang X. Wu X. Li L. Liu W. Wu R. A novel targeted iron oxide nanocarrier for inhibiting M2-type macrophages in the tumor microenvironment Journal of Cancer Research and Therapeutics 18 5 2022 1409 1416 10.4103/jcrt.jcrt_3_22 36204890
130 Liu J. Li W. Lin Y. Peng Y. Zhan M. Lai H. Chang Y. Li Y. Wong K. Chen B. Chen T. Tumor microenvironment-responsive metal nanotherapeutics for breast cancer chemo-/immunotherapy NPG Asia Mater 15 2023 1 14 10.1038/s41427-023-00473-0
131 Kusaczuk M. Krętowski R. Naumowicz M. Stypułkowska A. Cechowska-Pasko M. Silica nanoparticle-induced oxidative stress and mitochondrial damage is followed by activation of intrinsic apoptosis pathway in glioblastoma cells Int J Nanomedicine 13 2018 2279 2294 10.2147/IJN.S158393 29695906
132 Gu L. Ruff L.E. Qin Z. Corr M.P. Hedrick S.M. Sailor M.J. Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody Adv Mater 24 2012 3981 3987 10.1002/adma.201200776 22689074
133 Lisik K. Krokosz A. Application of carbon nanoparticles in oncology and regenerative medicine Int. J. Mol. Sci. 22 2021 8341 10.3390/ijms22158341 34361101
134 Zare-Zardini H. Hatamizadeh N. Haddadzadegan N. Soltaninejad H. Karimi-Zarchi M. Advantages and disadvantages of using Carbon Nanostructures in Reproductive Medicine: two sides of the same coin JBRA Assist Reprod 26 2022 142 144 10.5935/1518-0557.20210070 34672186
135 Carvalho A. Fernandes A.R. Baptista P.V. Chapter 10 - nanoparticles as delivery systems in cancer therapy: focus on gold nanoparticles and drugs Mohapatra S.S. Ranjan S. Dasgupta N. Mishra R.K. Thomas S. Applications of Targeted Nano Drugs and Delivery Systems 2019 Elsevier 257 295 10.1016/B978-0-12-814029-1.00010-7
136 Ghaffari A. Abazari M. Moghimi H.R. Chapter 4 - wound healing and nanotechnology: opportunities and challenges Barabadi H. Saravanan M. Mostafavi E. Vahidi H. Bioengineered Nanomaterials for Wound Healing and Infection Control 2023 Woodhead Publishing 115 174 10.1016/B978-0-323-95376-4.00014-9
137 Govardhane S. Shende P. Polymeric-ceramic nanocomposites toxicity Hussain C.M. Thomas S. Handbook of Polymer and Ceramic Nanotechnology 2020 Springer International Publishing Cham 1 20 10.1007/978-3-030-10614-0_55-1
138 Ghasemiyeh P. Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages Res Pharm Sci 13 2018 288 303 10.4103/1735-5362.235156 30065762
139 Kahraman E. Güngör S. Özsoy Y. Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery Ther. Deliv. 8 2017 967 985 10.4155/tde-2017-0075 29061106
140 Rout S.R. Bandaru R. Kenguva G. Hasan N. Alam M.S. Shukla R. Almalki W.H. Kesharwani P. Dandela R. 11 - dendrimers in photodynamic therapy Kesharwani P. Nanomaterials for Photodynamic Therapy 2023 Woodhead Publishing 281 305 10.1016/B978-0-323-85595-2.00004-9
141 Li X. Naeem A. Xiao S. Hu L. Zhang J. Zheng Q. Safety challenges and application strategies for the use of dendrimers in medicine Pharmaceutics 14 2022 1292 10.3390/pharmaceutics14061292 35745863
142 Zamora-Justo J.A. Abrica-González P. Vázquez-Martínez G.R. Muñoz-Diosdado A. Balderas-López J.A. Ibáñez-Hernández M. Polyethylene glycol-coated gold nanoparticles as DNA and atorvastatin delivery systems and cytotoxicity evaluation J. Nanomater. 2019 2019 5982047 10.1155/2019/5982047
143 Alhalili Z. Metal oxides nanoparticles: general structural description, chemical, physical, and biological synthesis methods, role in pesticides and heavy metal removal through wastewater treatment Molecules 28 2023 3086 10.3390/molecules28073086 37049850
144 Koyale P.A. Panda D.K. Delekar S.D. 1 - metal oxide engineering Delekar S.D. Advances in Metal Oxides and Their Composites for Emerging Applications 2022 Elsevier 3 56 10.1016/B978-0-323-85705-5.00004-X
145 Sousa D. Ferreira D. Rodrigues J.L. Rodrigues L.R. Nanotechnology in targeted drug delivery and therapeutics Applications of Targeted Nano Drugs and Delivery Systems 2019 Elsevier 357 409 10.1016/B978-0-12-814029-1.00014-4
146 Sahu T. Ratre Y.K. Chauhan S. Bhaskar L.V.K.S. Nair M.P. Verma H.K. Nanotechnology based drug delivery system: current strategies and emerging therapeutic potential for medical science J. Drug Deliv. Sci. Technol. 63 2021 102487 10.1016/j.jddst.2021.102487
147 Ezike T.C. Okpala U.S. Onoja U.L. Nwike C.P. Ezeako E.C. Okpara O.J. Okoroafor C.C. Eze S.C. Kalu O.L. Odoh E.C. Nwadike U.G. Ogbodo J.O. Umeh B.U. Ossai E.C. Nwanguma B.C. Advances in drug delivery systems, challenges and future directions Heliyon 9 2023 e17488 10.1016/j.heliyon.2023.e17488
148 Vargason A.M. Anselmo A.C. Mitragotri S. The evolution of commercial drug delivery technologies Nat. Biomed. Eng. 5 2021 951 967 10.1038/s41551-021-00698-w 33795852
149 Sani A. Pourmadadi M. Shaghaghi M. Mahdi Eshaghi M. Shahmollaghamsary S. Arshad R. Fathi-karkan S. Rahdar A. Medina D.I. Pandey S. Revolutionizing anticancer drug delivery: exploring the potential of tamoxifen-loaded nanoformulations J. Drug Deliv. Sci. Technol. 86 2023 104642 10.1016/j.jddst.2023.104642
150 Day C.M. Hickey S.M. Song Y. Plush S.E. Garg S. Novel tamoxifen nanoformulations for improving breast cancer treatment: old wine in new bottles Molecules 25 2020 1182 10.3390/molecules25051182 32151063
151 Zhan C. Jin Y. Xu X. Shao J. Jin C. Antitumor therapy for breast cancer: focus on tumor‐associated macrophages and nanosized drug delivery systems Cancer Med. 12 2023 11049 11072 10.1002/cam4.5489 36794651
152 Zhao B. Li X. Kong Y. Wang W. Wen T. Zhang Y. Deng Z. Chen Y. Zheng X. Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy Front. Bioeng. Biotechnol. 10 2022 1010724 10.3389/fbioe.2022.1010724
153 Hu G. Guo M. Xu J. Wu F. Fan J. Huang Q. Yang G. Lv Z. Wang X. Jin Y. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation Front. Immunol. 10 2019 1998 10.3389/fimmu.2019.01998 31497026
154 Zhou L. Zou M. Xu Y. Lin P. Lei C. Xia X. Nano drug delivery system for tumor immunotherapy: next-generation therapeutics Front. Oncol. 12 2022 864301 10.3389/fonc.2022.864301
155 Gong T. Dong Z. Fu Y. Gong T. Deng L. Zhang Z. Hyaluronic acid modified doxorubicin loaded Fe 3 O 4 nanoparticles effectively inhibit breast cancer metastasis J. Mater. Chem. B 7 2019 5861 5872 10.1039/C9TB01250H 31512706
156 Shen S. Zhang Y. Chen K.-G. Luo Y.-L. Wang J. Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy Mol. Pharmaceutics 15 2018 3642 3653 10.1021/acs.molpharmaceut.7b00997
157 Jian H. Wang X. Song P. Wu X. Zheng R. Wang Y. Zhang H. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer Acta Biomater. 140 2022 518 529 10.1016/j.actbio.2021.12.014 34923096
158 Li X. Pan J. Li Y. Xu F. Hou J. Yang G. Zhou S. Development of a localized drug delivery system with a step-by-step cell internalization capacity for cancer immunotherapy ACS Nano 16 2022 5778 5794 10.1021/acsnano.1c10892 35324153
159 Sakhi M. Khan A. Iqbal Z. Khan I. Raza A. Ullah A. Nasir F. Khan S.A. Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab for the effective treatment of breast cancer Front. Pharmacol. 13 2022 855294 10.3389/fphar.2022.855294
160 Vivek R. Thangam R. Nipunbabu V. Ponraj T. Kannan S. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a “smart” drug delivery system to breast cancer cell therapy Int. J. Biol. Macromol. 65 2014 289 297 10.1016/j.ijbiomac.2014.01.054 24472507
161 Zhu R. Lang T. Yin Q. Li Y. Nano drug delivery systems improve metastatic breast cancer therapy Medical Review 1 2021 244 274 10.1515/mr-2021-0011 37724299
162 Navya P.N. Kaphle A. Srinivas S.P. Bhargava S.K. Rotello V.M. Daima H.K. Current trends and challenges in cancer management and therapy using designer nanomaterials Nano Convergence 6 2019 23 10.1186/s40580-019-0193-2 31304563
163 Chauhan I. Yasir M. Verma M. Singh A.P. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery Adv Pharm Bull 10 2020 150 165 10.34172/apb.2020.021 32373485
164 Sohel M. Biswas P. Al Amin Md Hossain MdA. Sultana H. Dey D. Aktar S. Setu A. Khan MdS. Paul P. Islam MdN. Rahman MdA. Kim B. Al Mamun A. Genistein, a potential phytochemical against breast cancer treatment-insight into the molecular mechanisms Processes 10 2022 415 10.3390/pr10020415
165 Naeem H. Momal U. Imran M. Shahbaz M. Hussain M. Alsagaby S.A. Al Abdulmonem W. Umar M. Mujtaba A. El-Ghorab A.H. Ghoneim M.M. Shaker M.E. Abdelgawad M.A. Al Jbawi E. Anticancer perspectives of genistein: a comprehensive review Int. J. Food Prop. 26 2023 3305 3341 10.1080/10942912.2023.2281257
166 Konstantinou E.K. Gioxari A. Dimitriou M. Panoutsopoulos G.I. Panagiotopoulos A.A. Molecular pathways of genistein activity in breast cancer cells IJMS 25 2024 5556 10.3390/ijms25105556 38791595
167 Annaji M. Poudel I. Boddu S.H.S. Arnold R.D. Tiwari A.K. Babu R.J. Resveratrol‐loaded nanomedicines for cancer applications Cancer Reports 4 2021 e1353 10.1002/cnr2.1353 33655717
168 Park S.Y. Chae S.Y. Park J.O. Lee K.J. Park G. Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells Oncol. Rep. 35 2016 3248 3256 10.3892/or.2016.4716 27035791
169 Gadiyar V. Patel G. Chen J. Vigil D. Ji N. Campbell V. Sharma K. Shi Y. Weiss M.M. Birge R.B. Davra V. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders Front. Immunol. 14 2023 1135373 10.3389/fimmu.2023.1135373
170 Shen X. Zhou S. Yang Y. Hong T. Xiang Z. Zhao J. Zhu C. Zeng L. Zhang L. TAM-targeted reeducation for enhanced cancer immunotherapy: mechanism and recent progress Front. Oncol. 12 2022 1034842 10.3389/fonc.2022.1034842
171 Rodell C.B. Arlauckas S.P. Cuccarese M.F. Garris C.S. Li R. Ahmed M.S. Kohler R.H. Pittet M.J. Weissleder R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy Nat. Biomed. Eng. 2 2018 578 588 10.1038/s41551-018-0236-8 31015631
172 Huang J. Zhang H. Yu Y. Chen Y. Wang D. Zhang G. Zhou G. Liu J. Sun Z. Sun D. Lu Y. Zhong Y. Biodegradable self-assembled nanoparticles of poly (d,l-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer Biomaterials 35 2014 550 566 10.1016/j.biomaterials.2013.09.089 24135268
173 Zhang L. Ren Y. Wang Y. He Y. Feng W. Song C. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide IJN 13 2018 1097 1105 10.2147/IJN.S150512 29520138
174 Jung K. Heishi T. Khan O.F. Kowalski P.S. Incio J. Rahbari N.N. Chung E. Clark J.W. Willett C.G. Luster A.D. Yun S.H. Langer R. Anderson D.G. Padera T.P. Jain R.K. Fukumura D. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy J. Clin. Invest. 127 2017 3039 3051 10.1172/JCI93182 28691930
175 Wei X. Liu L. Li X. Wang Y. Guo X. Zhao J. Zhou S. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy J. Contr. Release 313 2019 42 53 10.1016/j.jconrel.2019.09.021
176 Du Y. Liang X. Li Y. Sun T. Jin Z. Xue H. Tian J. Nuclear and fluorescent labeled PD-1-liposome-DOX- 64 Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy Mol. Pharmaceutics 14 2017 3978 3986 10.1021/acs.molpharmaceut.7b00649
177 Yoon J. Le X.T. Kim J. Lee H. Nguyen N.T. Lee W.T. Lee E.S. Oh K.T. Choi H.-G. Youn Y.S. Macrophage-reprogramming upconverting nanoparticles for enhanced TAM-mediated antitumor therapy of hypoxic breast cancer J. Contr. Release 360 2023 482 495 10.1016/j.jconrel.2023.07.009
